In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of MBX Biosciences Inc (NASDAQ: MBX) closed at $8.85 in the last session, up 1.72% from day before closing price of $8.70. In other words, the price has increased by $1.72 from its previous closing price. On the day, 0.56 million shares were traded. MBX stock price reached its highest trading level at $9.6866 during the session, while it also had its lowest trading level at $8.72.
Ratios:
We take a closer look at MBX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 25.75 and its Current Ratio is at 25.75. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on October 08, 2024, initiated with a Buy rating and assigned the stock a target price of $40.
On October 08, 2024, JP Morgan started tracking the stock assigning a Overweight rating and target price of $30.
On October 08, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $35.Jefferies initiated its Buy rating on October 08, 2024, with a $35 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 18 ’25 when GORDON CARL L bought 143,170 shares for $10.84 per share. The transaction valued at 1,551,963 led to the insider holds 3,255,000 shares of the business.
GORDON CARL L bought 47,502 shares of MBX for $468,793 on Feb 14 ’25. The Director now owns 3,205,930 shares after completing the transaction at $9.87 per share. On Feb 18 ’25, another insider, ORBIMED ADVISORS LLC, who serves as the Director of the company, bought 143,170 shares for $10.84 each. As a result, the insider paid 1,551,963 and bolstered with 3,255,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MBX now has a Market Capitalization of 295744000 and an Enterprise Value of 13878537.
Stock Price History:
Over the past 52 weeks, MBX has reached a high of $27.50, while it has fallen to a 52-week low of $8.54. The 50-Day Moving Average of the stock is -20.34%, while the 200-Day Moving Average is calculated to be -49.18%.
Shares Statistics:
According to the various share statistics, MBX traded on average about 307.61K shares per day over the past 3-months and 219090 shares per day over the past 10 days. A total of 33.38M shares are outstanding, with a floating share count of 16.00M. Insiders hold about 52.13% of the company’s shares, while institutions hold 50.09% stake in the company. Shares short for MBX as of 1740700800 were 4109163 with a Short Ratio of 13.36, compared to 1738281600 on 2799627.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Currently, 1 analysts are dedicated to thoroughly evaluating and rating the performance of MBX Biosciences Inc (MBX) in the stock market.The consensus estimate for the next quarter is -$0.55, with high estimates of -$0.55 and low estimates of -$0.55.
Analysts are recommending an EPS of between -$1.99 and -$2.53 for the fiscal current year, implying an average EPS of -$2.3. EPS for the following year is -$2.34, with 3.0 analysts recommending between -$2.14 and -$2.63.
